切换导航
搜索
PD-1 PD-L1 IgG2a CD3ε CD28 Ly6G IFNγ IL-4
中文 | English
询价

InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar)

货号 #SIM0038
克隆号:
Tislelizumab
反应种属:
Human

￥2,448 - ￥84,656

选择参数
  • 100 mg - ￥84,656
  • 50 mg - ￥47,568
  • 25 mg - ￥33,088
  • 5 mg - ￥9,472
  • 1 mg - ￥2,448
  • 定制包装(请询价)
<em>InVivo</em>SIM anti-human PD-1 (Tislelizumab Biosimilar)
产品说明书 安全数据表

产品详情

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Tislelizumab making it ideal for research use. This Tislelizumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. The structure of Tislelizumab has been modified to maximally inhibit the binding of PD-1 to PD-L1 and minimize the binding of Tislelizumab to Fcγ receptors. The epitope of Tislelizumab is formed on the CC′ loop of the front β sheet face of PD-1, which is innovative among anti-PD-1 antibodies; in comparison, other PD-1 antibodies, like Nivolumab and Pembrolizumab, bind to the N-terminal region and the C’D loop of PD-1, respectively. Tislelizumab is able to bind to human PD-1 with high specificity and affinity, with the disassociation constant being 0.15 nmol/L. At the 5 mg/kg dose, PD-1 receptor occupancy is >90%. In clinical studies, Tislelizumab has shown preliminary anti-tumor effects in various solid tumors.

参数

同种型 Human IgG4, κ
推荐的同型对照 RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme
推荐稀释缓冲液 InVivoPure pH 7.0 Dilution Buffer
免疫原 Human PD-1
Reported Applications Blocking of PD-1/PD-L signaling Functional assays ELISA
形式 PBS, pH 7.0 Contains no stabilizers or preservatives
内毒素 <0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay
聚合 <5% Determined by SEC
纯化 >95% Determined by SDS-PAGE
无菌性 0.2 μM filtration
生产 Purified from cell culture supernatant in an animal-free facility
提纯 Protein A
分子量 150 kDa
小鼠病原体试验 Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Minute Virus: Negative Mouse Hepatitis Virus: Negative Reovirus Screen: Negative Lymphocytic Choriomeningitis virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Mouse Rotavirus: Negative Theiler's Murine Encephalomyelitis: Negative Ectromelia/Mousepox Virus: Negative Hantavirus: Negative Polyoma Virus: Negative Mouse Adenovirus: Negative Sendai Virus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Mouse Cytomegalovirus: Negative K Virus: Negative
保存 The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

推荐产品

相关产品

  1. InVivoMAb anti-mouse PD-1 (CD279)
  2. InVivoMAb anti-mouse PD-1 (CD279)
  3. InVivoMAb anti-human PD-1 (CD279)
  4. InVivoMAb anti-human PD-1 (CD279)
  5. InVivoMAb anti-mouse PD-1 (CD279)
  6. InVivoPlus anti-mouse PD-1 (CD279)
  7. InVivoPlus anti-mouse PD-1 (CD279)
  8. InVivoPlus anti-mouse PD-1 (CD279)
  9. RecombiMAb anti-mouse PD-1 (CD279) (D265A)
  10. RecombiMAb anti-mouse PD-1 (CD279) (D265A)
  11. RecombiMAb anti-mouse PD-1 (CD279) (D265A)
  12. RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG)
  13. RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG)
  14. RecombiMAb anti-mouse PD-1 (CD279)
  15. RecombiMAb anti-mouse PD-1 (CD279)
  16. RecombiMAb anti-mouse PD-1 (CD279)
  17. RecombiMAb anti-mouse PD-1 (CD279)
  18. RecombiMAb anti-mouse PD-1 (CD279)
  19. InVivoSIM anti-human PD-1 (Nivolumab Biosimilar)
  20. InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar)
  21. InVivoSIM anti-human PD-1 (Cemiplimab Biosimilar)
点击关闭